|Bid||15.97 x 100|
|Ask||15.98 x 200|
|Day's Range||15.78 - 16.01|
|52 Week Range||11.44 - 17.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Amicus Therapeutics Inc (NASDAQ:FOLD), with a market capitalization of US$2.89b, rarely draw their attention from the investingRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...
Amicus Therapeutics Inc’s (NASDAQ:FOLD): Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The US$2.68B market-cap company announcedRead More...
The Cranbury, New Jersey-based company said it had a loss of 28 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
Amicus Therapeutics (FOLD) generated net product sales of $36.9 million in 2017 compared to $4.9 million in 2016. For 2018, 2019 and 2020, Amicus is expected to generate revenues of $85.3 million, $180.2 million, and $255.6 million, respectively, on the back of new geographic approvals and Galafold’s market penetration. Amicus incurred a cost of goods sold of $833,000 in 2016 compared to $6.2 million in 2017.
According to the American Journal of Human Genetics, newborn screening studies in Italy, Taiwan, and Austria found the incidence of Fabry disease mutations to be between 1:2,400 and 1:4,000—more than ten times higher than previous studies. At present, Galafold has two competitors: agalsidase beta and agalsidase alfa.
Amicus Therapeutics (FOLD) is currently developing a novel proprietary enzyme replacement therapy (or ERT) coformulated with migalastat HC1 for Fabry disease patients with nonamenable genetic mutations. The therapy is currently in late preclinical development. The future value driver of the company’s research pipeline is ATB200/AT2221, a novel, late-stage treatment for Pompe disease.
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.
UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.
Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
Athenex and Amicus Therapeutics are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the future outlookRead More...
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amicus Therapeutics, Inc. Here are 5 ETFs with the largest exposure to FOLD-US. Comparing the performance and risk of Amicus Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)